Loading
Personalis, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Feb 2026.
Personalis, Inc.: what insiders have been doing
Every trade that managers of Personalis, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. 14 insiders have disclosed 30 filings since 18 October 2025.
On the market, 1 insider bought (1 purchase totalling €428k) while 4 insiders sold (8 sales totalling €3.1M). The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Chen Richard filed the largest sale, €1.3M, on 15 July 2026, which represents 0.086% of the company's market value.
The latest purchase dates back some time: it was published 247 days ago, on 13 February 2026. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,814 companies, median 19 filings), a count of 30 filings is above the norm. Looking back to 2021, when coverage begins, insiders filed 3 purchases and 104 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 69.6 m USD and net income at -81.3 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
171
Thresholds
n/a
Buy Volume
€882,219
3 ops. · all time
Sell Volume
€9M
104 ops. · all time
Who traded when
BuySaleRichard Chen7 sales
Aaron Tachibana6 sales
Christopher M. Hall5 sales
Stephen Michael Moore4 sales
Tempus AI, Inc.1 buy
Since the insiders bought
- -25.8%Entry US$8.57 · Close at T+90 US$6.36
- +141.1%Entry US$1.75 · Close at T+365 US$4.22
- -68.7%Entry US$9.26 · Close at T+365 US$2.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Personalis, Inc. Hold (neutral), based on 3 analysts. Average price target: US$15.17.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,104 of 24,148 companies
20.5
score / 100
Value22
Quality19
FCF yld-4.8%
Earn yld-4.9%
EV/EBITDA·
ROE-50%
Gross mgn23%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.90
Analyst consensus
3 analystsHold
US$13.00Target US$15.17(-5%)US$16.25
Income statement
RevenueUS$69.6M
Gross profitUS$15.8M23% margin
EBITDA-US$71M-102% margin
Net income-US$81.3M-153.8% margin
Valuation
PER (forward)-16.9x
P/Book7.2x
Beta2.32
Balance sheet & cash
Market capUS$1.7B
Total debtUS$39.9M
Free Cash Flow-US$79.5M
Debt / Equity16%
Profitability & ownership
ROE-50.3%
ROA-25.0%
% insiders26.1%
% institutions66.8%
Last declaration on 22 September 2026
Declarations171 total
2,931 shares@ US$16.220.0027% mcap8.3% of flowCommon StockSEC:0001401786-26-000009:0
2,068 shares@ US$16.220.0019% mcap42.9% of flowCommon StockSEC:0001915342-26-000004:0
3,998 shares@ US$16.220.0037% mcap3.2% of flowCommon StockSEC:0001779787-26-000005:0
7,459 shares@ US$16.220.0068% mcap6.7% of flowCommon StockSEC:0001449535-26-000008:0
100,000 shares@ US$15.030.085% mcap100.0% of flowCommonSEC144:0001950047-26-007108
100,000 shares@ US$2.440.014% mcap12.2% of flowCommon StockSEC:0001779787-26-000003:0
100,000 shares@ US$15.150.086% mcap75.9% of flowCommon StockSEC:0001779787-26-000003:1
100,000 shares@ US$14.110.079% mcap52.7% of flowCommonSEC144:0001950047-26-006983
100,000 shares@ US$1.610.0091% mcap9.0% of flowCommon StockSEC:0001449535-26-000006:0
100,000 shares@ US$15.080.085% mcap84.3% of flowCommon StockSEC:0001449535-26-000006:1
4,982 shares@ US$13.020.0037% mcap100.0% of flowCommonSEC144:0001950047-26-006609
100,000 shares@ US$12.590.086% mcap47.3% of flowCommonSEC144:0001950047-26-006542
51,251 shares@ US$12.590.044% mcap100.0% of flowCommonSEC144:0001950047-26-006545
100,000 sharesCommon StockSEC:0001449535-26-000004:0
100,000 sharesCommon StockSEC:0001449535-26-000004:1
40,000 shares@ US$10.780.029% mcap100.0% of flowCommonSEC144:0001950047-26-005657
6,250 shares0Common StockSEC:0001231845-26-000001:0
6,250 shares0Common StockSEC:0001008891-26-000001:0
6,250 shares0Common StockSEC:0001501545-26-000001:0
6,250 shares0Common StockSEC:0001471716-26-000001:0
6,250 shares0Common StockSEC:0001065168-26-000001:0
6,250 shares0Common StockSEC:0001243399-26-000001:0
46,875 shares0Common StockSEC:0001779787-26-000002:0
28,125 shares0Common StockSEC:0001915342-26-000002:0
87,500 shares0Common StockSEC:0001449535-26-000002:0
25 of 171 declarations
About Personalis, Inc.
Personalis, Inc. is a U.S.-based precision genomics company listed on the NASDAQ (United States) under the ticker PSNL. Founded in 2011 by a team of next-generation sequencing leaders from Stanford, the company has built a differentiated position in precision oncology by focusing on deep molecular profiling of cancer and the immune response. Personalis is now headquartered in Fremont, California, where it operates a CLIA-certified, CAP-accredited laboratory. Its business model sits at the intersection of clinical genomics, biopharma services, and biomarker-driven oncology, making it a specialized player rather than a broad-based diagnostics company. ([investors.personalis.com](https://investors.personalis.com/?utm_source=openai))
The company’s core franchise is the NeXT platform, which is designed to generate highly comprehensive genomic and immune-based data from tumor samples. Personalis’ product and service portfolio includes NeXT Dx for comprehensive tumor profiling, ImmunoID NeXT for tumor and microenvironment characterization, and NeXT Personal MRD for ultrasensitive detection of minimal residual disease and cancer recurrence. In addition to these clinical and translational offerings, Personalis provides sequencing and biomarker services to biopharmaceutical customers for clinical trials, companion diagnostic development, and research programs. This mix gives the company exposure to both research-stage demand and the increasingly important clinical diagnostics market. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-inc-announces-launch-next-dxtm-test-comprehensive?utm_source=openai))
Read moreShow less
From a competitive standpoint, Personalis operates in a crowded and fast-moving market that includes molecular diagnostics companies, NGS platform providers, and oncology testing specialists. Its main differentiators are the breadth of its genomic coverage, the integration of tumor and immune-system information, and a long track record working with drug developers. The company has highlighted relationships with Moderna, Merck, Tempus, and the VA Million Veterans Program, which underscores both the quality of its scientific platform and the importance of strategic partnerships to its growth strategy. At the same time, those relationships also highlight customer concentration and execution risk. ([investors.personalis.com](https://investors.personalis.com/news-releases/news-release-details/personalis-reports-fourth-quarter-and-full-year-2025-results-and?utm_source=openai))
Recent developments suggest that Personalis is increasingly transitioning from a research-enablement story toward a clinical-commercial execution story. In its latest public updates, the company emphasized strong growth in clinical test volumes, milestone Medicare coverage wins for breast cancer recurrence surveillance and stage I-III NSCLC, and an expanded agreement with Tempus to market NeXT Personal Dx in colorectal cancer. Management also announced a CEO retirement and transition, with founder John West stepping back after a long career in DNA sequencing. For investors, PSNL remains a high-risk, catalyst-driven NASDAQ name: the upside depends on reimbursement, clinical adoption, and the ability to turn its scientific differentiation into sustainable revenue growth. ([investors.personalis.com](https://investors.personalis.com/node/8851/pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
